Company profile
Longeveron Inc.
NASDAQ: LGVN · Healthcare · Biotechnology
#858 of 1,420 Healthcare companies by revenuebottom-quartile growth
EA Score
30DFH 23DQ 37GM 29SS 40
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$1.2M
Rev growth YoY (TTM)
-42.7%
Net income (FY)
-$22.7M
Employees
38
as of 2026-08-22
Market cap
$16.8M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.2M$1.2M2025
Net income-$22.7M-$22.7M2025
Operating income-$23.3M-$23.3M2025
Total assets$10.3M$10.3M2025
Liabilities$4.6M$4.6M2025
Equity$5.7M$5.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Longeveron Inc.’s revenue?
Longeveron Inc. booked $1.2M in FY2025 revenue, contracting 50% year over year — slower than 81% of Healthcare companies we track, at a -1893.6% net margin.
Peers · Healthcare
Baudax Bio, Inc.——SeaStar Medical Holding Corporation30DNRx Pharmaceuticals, Inc.24DSOHM, Inc.61CPeoplesway.com Inc.——Ampio Pharmaceuticals, Inc.——Neighbors
Miami-Dade →Key facts
CEOStephen H. Willard
SectorHealthcare
IndustryBiotechnology
HeadquartersMiami, FL
ExchangeNASDAQ: LGVN
Employees38
IPO date2021-02-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.